We are contrasting Zymeworks Inc. (NYSE:ZYME) and Iovance Biotherapeutics Inc. (NASDAQ:IOVA) on their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks Inc.	53.02M	9.65	36.56M	-0.35	0.00
Iovance Biotherapeutics Inc.	N/A	0.00	123.58M	-1.37	0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Zymeworks Inc. and Iovance Biotherapeutics Inc.

Profitability

Table 2 has Zymeworks Inc. and Iovance Biotherapeutics Inc.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Zymeworks Inc.	-68.96%	-9.2%	-8%
Iovance Biotherapeutics Inc.	0.00%	-43.7%	-41.3%

Liquidity

The Current Ratio of Zymeworks Inc. is 6.4 while its Quick Ratio stands at 6.4. The Current Ratio of rival Iovance Biotherapeutics Inc. is 15.9 and its Quick Ratio is has 15.9. Iovance Biotherapeutics Inc. is better equipped to clear short and long-term obligations than Zymeworks Inc.

Institutional & Insider Ownership

The shares of both Zymeworks Inc. and Iovance Biotherapeutics Inc. are owned by institutional investors at 40.3% and 0% respectively. Zymeworks Inc.’s share owned by insiders are 10.3%. On the other hand, insiders owned about 0.4% of Iovance Biotherapeutics Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Zymeworks Inc.	0.27%	-5.78%	11.19%	5.33%	44.04%	2.25%
Iovance Biotherapeutics Inc.	7.34%	23.06%	21.6%	-31.55%	-37.96%	27.23%

For the past year Zymeworks Inc. was less bullish than Iovance Biotherapeutics Inc.

Summary

Zymeworks Inc. beats on 6 of the 9 factors Iovance Biotherapeutics Inc.

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companyÂ’s lead product candidate include ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast, gastric, and ovarian cancers. It is also developing ZW33, a bispecific anti-human epidermal growth factor receptor 2 antibody-drug conjugate that is in preclinical development stage for the treatment of breast and ovarian cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Celgene Corporation and Celgene Alpine Investment Co. LLC, GlaxoSmithKline Intellectual Property Development Limited, and Daiichi Sankyo Co., Ltd. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The companyÂ’s lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patientsÂ’ tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patientÂ’s TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas MD Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.